Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chlormerodrin Hg-197 is a radiopharmaceutical diagnostic agent consisting of the organomercurial compound chlormerodrin labeled with the radioactive isotope mercury-197. Historically, it was utilized in nuclear medicine for scintigraphic imaging, particularly for the localization of brain tumors and for renal cortical scanning to evaluate kidney structure and function. The agent functions by accumulating in the renal tubules through binding to sulfhydryl groups and by localizing in brain lesions where the blood-brain barrier is compromised. While the non-radiolabeled form of chlormerodrin was previously used as a diuretic for heart failure, the radiolabeled version has been largely superseded by technetium-99m-based imaging agents due to their superior imaging characteristics and lower radiation burden.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlormerodrin Hg-197.